GHRP-6.
First-generation GH-releasing hexapeptide with appetite-stimulating side effect.
Build your bag, then either book a consultation (an EU-licensed physician reviews your file — anything declined is refunded) or upload an existing Rx at checkout.
- ✓Magistral preparation — Directive 2001/83/EC Art. 5(1).
- ✓Patient-named prescription only — dispensed against a valid Rx.
- ✓EU-GMP Annex 1 Grade A/B cleanroom compounding.
- ✓Cold-chain shipping across EU/EEA — 2–5 working days.
About GHRP-6.
GHRP-6 is a hexapeptide and one of the earliest synthetic ghrelin-receptor agonists developed. It produces a strong GH pulse and is also known for a characteristic appetite-stimulating side effect, which can be useful in cachectic or low-appetite patients but undesirable in body-composition protocols.
Compared with Ipamorelin, GHRP-6 is less selective for GHS-R1a, so it can produce modest cortisol and prolactin elevations. Modern protocols generally favour ipamorelin unless the appetite effect is specifically wanted.
GHRP-6 activates the ghrelin / GHS-R1a receptor on pituitary somatotrophs, releasing GH in a pulsatile fashion. It also signals through ghrelin receptors in the hypothalamic arcuate nucleus, which drives the appetite effect.
Subcutaneous injection, typically 100 mcg, 2–3 times per day. Bedtime administration leverages the natural nocturnal GH peak.
Your physician sets the prescription. This is descriptive information, not a self-administration guide.
Lyophilised: store at 2–8 °C, protect from light. Once reconstituted: 2–8 °C, use within 30 days. Do not freeze.
- INN / Name
- GHRP-6
- Form
- Lyophilised vial · subcutaneous injection
- Strength
- 5mg vial
- Manufacturing
- EU-GMP Annex 1 · Grade A/B
- Endotoxins
- European Pharmacopoeia 2.6.14 · LAL assay
- Identity & purity
- HPLC + MS · > 98%
- Cold chain
- Validated 2–8 °C, monitored end-to-end
- Regulatory basis
- Directive 2001/83/EC · Article 5(1)
2–5 working days
EU / EEA cold-chain delivery, 2–8 °C monitored end-to-end with digital temperature log. Tracking link sent on dispatch.
Magistral preparation
Patient-named preparation under Directive 2001/83/EC Article 5(1). Dispensed exclusively against a valid EU prescription.
EU prescription recognition
Prescriptions written in one EU member state are recognised in others under Directive 2011/24/EU on cross-border healthcare.
Within Growth Hormone.
- Cat. 03
Sermorelin
GHRH analogue that prompts the pituitary to release endogenous growth hormone in physiological pulses.
€50.00 - Cat. 03
Ipamorelin
Selective ghrelin-receptor agonist with minimal cortisol or prolactin elevation.
€45.00 - Cat. 03
CJC-1295
GHRH analogue — DAC variant gives sustained release, NO-DAC mimics native pulsatility.
€80.00